Telix Withdraws Marketing Application for Illuccix in Europe
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Final IPAX-1 Study Data Confirms Safety Tolerability Profile
- 1H 2022 - Results Presentation
- Appendix 4D - Results for announcement to the market
- Grand Pharmaceutical Groups investment in Telix
- APAC Regulatory Progress Prostate and Kidney Cancer Imaging
Later from Telix Pharmaceuticals
- Chinese NMPA Approves TLX250 Phase III registration study
- Health Canada Approves Illuccix for Prostate Cancer Imaging
- Expansion of partnership with GE Healthcare in PET imaging
- TLX250-CDx Indication Expansion - Preliminary Data
- Appendix 4C and Activities Report - September 2022 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals